Ceapro Inc. Reports 2021 Third Quarter and Nine-Month Financial Results and Operational Highlights
– Increased R&D activities focused on the completion of a clinical trial for oat beta glucan as a potential cholesterol reducer and on the development of yeast beta glucan as a potential inhalable therapeutic for COVID-19 –
– Q3 2021 record sales of $4,523,000 compared to $3,476,000 for Q3 2020, representing a 30% increase –
– Net profit of $875,000 for Q3 2021 vs. net profit of $192,000 for Q3 2020, a 356% increase –
– Achieved record production levels despite COVID-19 pandemic situation –